<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434667</url>
  </required_header>
  <id_info>
    <org_study_id>R01HG002213</org_study_id>
    <secondary_id>R01HG002213</secondary_id>
    <nct_id>NCT01434667</nct_id>
  </id_info>
  <brief_title>Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV</brief_title>
  <official_title>Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Human Genome Research Institute (NHGRI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Howard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to examine the impact of receiving a genetic risk assessment for
      Alzheimer's disease (AD) among individuals with Mild Cognitive Impairment (MCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease is a common condition affecting memory and thinking. Genes can sometimes
      be used to provide risk estimates for the eventual development of certain common diseases.
      Apolipoprotein E (APOE) is one gene which can provide information about a person's chances of
      developing Alzheimer's disease.

      Some people with a diagnosis of Mild Cognitive Impairment (MCI) are curious to learn more
      about the chance of developing Alzheimer's disease. In the REVEAL IV Study, we are examining
      the psychological and behavioral impact of learning genetic risk information pertaining to
      the chance for an individual with MCI to progress to dementia of the Alzheimer's type within
      three years.

      Participation in this study requires an initial phone call which will elicit some demographic
      information about the participant and his or her study partner. A first in-person visit to
      the research clinic will consist of an education session, the administration of knowledge and
      attitudinal surveys and some tests to assess memory and thinking skills. This visit will take
      approximately 2-3 hours. Participants with MCI will have their blood drawn for genetic
      testing. Participants will then be randomized to one of two groups. Those in the intervention
      arm will receive a three-year risk estimate for the chance of progressing to dementia of the
      Alzheimer's type based on age, the diagnosis of MCI and their own APOE gene test result.
      Those in the comparison arm will receive a three-year risk estimate for the chance of
      progressing to dementia of the Alzheimer's type based on age and the diagnosis of MCI,
      without the APOE gene test result. Participants randomized to the comparison arm will have
      the opportunity to learn their own APOE gene test result at the end of the study.
      Participants and their study partners will be followed for 6 months following disclosure of
      results with 1 additional clinic visit and 1 additional phone interviews.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Geriatric Depression Rating Scale</measure>
    <time_frame>Change from Baseline at 6 Weeks, 6 Months and 12 Months Post-disclosure</time_frame>
    <description>Validated scale of depression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Mini-State Trait Anxiety Inventory</measure>
    <time_frame>Change from Baseline at 6 Weeks, 6 Months and 12 Months Post-disclosure</time_frame>
    <description>Validated scale of anxiety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Test-Specific Distress</measure>
    <time_frame>1-3 Days, 6 Weeks, 6 Months and 12 Months Post-disclosure</time_frame>
    <description>Validated scale that assesses two common responses related to a specific stressful life event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological Impact of Test Disclosure (IGT-AD)</measure>
    <time_frame>6 Weeks, 6 Months and 12 Months Post-disclosure</time_frame>
    <description>A measure designed to assess the impact of genetic test result disclosure across three domains: distress, uncertainty and positive experiences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recall and Comprehension of Risk Information</measure>
    <time_frame>6 Weeks, 6 Months and 12 Months Post-disclosure</time_frame>
    <description>Several measures to assess participant recall and comprehension of personalized risk information for AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction</measure>
    <time_frame>Baseline, 6 Weeks, 6 Months and 12 Months Post-disclosure</time_frame>
    <description>How well participants' pre-test expectations are met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User Ratings of Risk Assessment Experience</measure>
    <time_frame>Baseline</time_frame>
    <description>Subjective ratings of the impact and utility of risk assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Behavior and Insurance Changes</measure>
    <time_frame>6 Weeks, 6 Months and 12 Months Post-disclosure</time_frame>
    <description>Examine behavior changes, advance planning changes, insurance changes, medication changes, enrollment in clinical research.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>APOE Genotype Non-Disclosure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>APOE Genotype Disclosure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>APOE genotype disclosure and Alzheimer's disease risk disclosure</intervention_name>
    <description>Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.</description>
    <arm_group_label>APOE Genotype Disclosure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Alzheimer's disease risk disclosure</intervention_name>
    <description>Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.</description>
    <arm_group_label>APOE Genotype Non-Disclosure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with Mild Cognitive Impairment (amnestic-MCI as defined by the Petersen
             criteria)

          -  Individuals who have a close friend, relative or spouse willing to be a study partner.
             Study partners attend each study visit with the participant and also complete surveys
             and interviews.

        Exclusion Criteria:

          -  Individuals with current, untreated anxiety or depression

          -  Individuals who do not meet the criteria for amnestic-MCI

          -  Individuals who have the diagnosis of dementia or Alzheimer's disease

          -  Individuals not fluent in English

          -  Individuals who do not have a study partner
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C Green, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital/Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alz.org/alzheimers_disease_mild_cognitive_impairment.asp</url>
    <description>Alzheimer's Association - Educational Materials on Mild Cognitive Impairment</description>
  </link>
  <link>
    <url>http://www.alz.org/alzheimers_disease_causes_risk_factors.asp</url>
    <description>Alzheimer's Association - Educational Materials on Risk Factors</description>
  </link>
  <reference>
    <citation>Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC. Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet Test Mol Biomarkers. 2011 Dec;15(12):871-5. doi: 10.1089/gtmb.2011.0028. Epub 2011 Jul 12.</citation>
    <PMID>21749214</PMID>
  </reference>
  <reference>
    <citation>Akinleye I, Roberts JS, Royal CD, Linnenbringer E, Obisesan TO, Fasaye GA, Green RC. Differences between African American and White research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease. J Genet Couns. 2011 Dec;20(6):650-9. doi: 10.1007/s10897-011-9377-6. Epub 2011 Jun 9.</citation>
    <PMID>21656311</PMID>
  </reference>
  <reference>
    <citation>Christensen KD, Roberts JS, Uhlmann WR, Green RC. Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Genet Med. 2011 May;13(5):409-14. doi: 10.1097/GIM.0b013e3182076bf1.</citation>
    <PMID>21270636</PMID>
  </reference>
  <reference>
    <citation>Roberts JS, Karlawish JH, Uhlmann WR, Petersen RC, Green RC. Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members. Neurology. 2010 Aug 3;75(5):425-31. doi: 10.1212/WNL.0b013e3181eb5872.</citation>
    <PMID>20679636</PMID>
  </reference>
  <reference>
    <citation>Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC. The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study. Eur J Hum Genet. 2010 Dec;18(12):1296-301. doi: 10.1038/ejhg.2010.119. Epub 2010 Jul 28.</citation>
    <PMID>20664629</PMID>
  </reference>
  <reference>
    <citation>Vernarelli JA, Roberts JS, Hiraki S, Chen CA, Cupples LA, Green RC. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr. 2010 May;91(5):1402-7. doi: 10.3945/ajcn.2009.28981. Epub 2010 Mar 10.</citation>
    <PMID>20219963</PMID>
  </reference>
  <reference>
    <citation>Linnenbringer E, Roberts JS, Hiraki S, Cupples LA, Green RC. &quot;I know what you told me, but this is what I think:&quot; perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med. 2010 Apr;12(4):219-27. doi: 10.1097/GIM.0b013e3181cef9e1.</citation>
    <PMID>20139767</PMID>
  </reference>
  <reference>
    <citation>Taylor DH Jr, Cook-Deegan RM, Hiraki S, Roberts JS, Blazer DG, Green RC. Genetic testing for Alzheimer's and long-term care insurance. Health Aff (Millwood). 2010 Jan-Feb;29(1):102-8. doi: 10.1377/hlthaff.2009.0525.</citation>
    <PMID>20048367</PMID>
  </reference>
  <reference>
    <citation>Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC. Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. J Health Commun. 2009 Dec;14(8):768-84. doi: 10.1080/10810730903295518.</citation>
    <PMID>20029710</PMID>
  </reference>
  <reference>
    <citation>Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA; REVEAL Study Group. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009 Jul 16;361(3):245-54. doi: 10.1056/NEJMoa0809578.</citation>
    <PMID>19605829</PMID>
  </reference>
  <reference>
    <citation>Chung WW, Chen CA, Cupples LA, Roberts JS, Hiraki SC, Nair AK, Green RC, Stern RA. A new scale measuring psychologic impact of genetic susceptibility testing for Alzheimer disease. Alzheimer Dis Assoc Disord. 2009 Jan-Mar;23(1):50-6.</citation>
    <PMID>19266699</PMID>
  </reference>
  <reference>
    <citation>Cassidy MR, Roberts JS, Bird TD, Steinbart EJ, Cupples LA, Chen CA, Linnenbringer E, Green RC. Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Alzheimers Dement. 2008 Nov;4(6):406-13. doi: 10.1016/j.jalz.2008.04.007.</citation>
    <PMID>19012865</PMID>
  </reference>
  <reference>
    <citation>Hiraki S, Chen CA, Roberts JS, Cupples LA, Green RC. Perceptions of familial risk in those seeking a genetic risk assessment for Alzheimer's disease. J Genet Couns. 2009 Apr;18(2):130-6. doi: 10.1007/s10897-008-9194-8. Epub 2008 Oct 23.</citation>
    <PMID>18949541</PMID>
  </reference>
  <reference>
    <citation>Fanshawe TR, Prevost AT, Roberts JS, Green RC, Armstrong D, Marteau TM. Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates. Genet Test. 2008 Sep;12(3):381-6. doi: 10.1089/gte.2007.0103.</citation>
    <PMID>18666860</PMID>
  </reference>
  <reference>
    <citation>Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):94-7. doi: 10.1097/WAD.0b013e31815a9dcc.</citation>
    <PMID>18317253</PMID>
  </reference>
  <reference>
    <citation>Eckert SL, Katzen H, Roberts JS, Barber M, Ravdin LD, Relkin NR, Whitehouse PJ, Green RC. Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study. Genet Med. 2006 Dec;8(12):746-51.</citation>
    <PMID>17172937</PMID>
  </reference>
  <reference>
    <citation>Gooding HC, Linnenbringer EL, Burack J, Roberts JS, Green RC, Biesecker BB. Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns. 2006 Dec;64(1-3):259-67. Epub 2006 Jul 21.</citation>
    <PMID>16860524</PMID>
  </reference>
  <reference>
    <citation>Hurley AC, Harvey FR, Roberts JS, Wilson-Chase C, Lloyd S, Prest J, Lock M, Horvath KJ, Green RC. Genetic susceptibility for Alzheimer's disease: why did adult offspring seek testing? Am J Alzheimers Dis Other Demen. 2005 Nov-Dec;20(6):374-81.</citation>
    <PMID>16396443</PMID>
  </reference>
  <reference>
    <citation>Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC; REVEAL (Risk Evaluation and Education for Alzheimer's Disease) Study Group. Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol. 2005 Dec;18(4):250-5.</citation>
    <PMID>16306249</PMID>
  </reference>
  <reference>
    <citation>Marteau TM, Roberts S, LaRusse S, Green RC. Predictive genetic testing for Alzheimer's disease: impact upon risk perception. Risk Anal. 2005 Apr;25(2):397-404.</citation>
    <PMID>15876213</PMID>
  </reference>
  <reference>
    <citation>Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff (Millwood). 2005 Mar-Apr;24(2):483-90.</citation>
    <PMID>15757934</PMID>
  </reference>
  <reference>
    <citation>LaRusse S, Roberts JS, Marteau TM, Katzen H, Linnenbringer EL, Barber M, Whitehouse P, Quaid K, Brown T, Green RC, Relkin NR. Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease. Genet Med. 2005 Jan;7(1):48-53.</citation>
    <PMID>15654228</PMID>
  </reference>
  <reference>
    <citation>Roberts JS, Barber M, Brown TM, Cupples LA, Farrer LA, LaRusse SA, Post SG, Quaid KA, Ravdin LD, Relkin NR, Sadovnick AD, Whitehouse PJ, Woodard JL, Green RC. Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med. 2004 Jul-Aug;6(4):197-203.</citation>
    <PMID>15266207</PMID>
  </reference>
  <reference>
    <citation>Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med. 2004 Jul-Aug;6(4):192-6.</citation>
    <PMID>15266206</PMID>
  </reference>
  <reference>
    <citation>Hipps YG, Roberts JS, Farrer LA, Green RC. Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer's disease. Genet Test. 2003 Spring;7(1):39-44.</citation>
    <PMID>12820701</PMID>
  </reference>
  <reference>
    <citation>Roberts JS, LaRusse SA, Katzen H, Whitehouse PJ, Barber M, Post SG, Relkin N, Quaid K, Pietrzak RH, Cupples LA, Farrer LA, Brown T, Green RC. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord. 2003 Apr-Jun;17(2):86-93.</citation>
    <PMID>12794385</PMID>
  </reference>
  <reference>
    <citation>Roberts JS, Connell CM, Cisewski D, Hipps YG, Demissie S, Green RC. Differences between African Americans and whites in their perceptions of Alzheimer disease. Alzheimer Dis Assoc Disord. 2003 Jan-Mar;17(1):19-26.</citation>
    <PMID>12621316</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2011</study_first_submitted>
  <study_first_submitted_qc>September 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2011</study_first_posted>
  <last_update_submitted>July 30, 2013</last_update_submitted>
  <last_update_submitted_qc>July 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Robert C. Green, MD, MPH</investigator_full_name>
    <investigator_title>Principal Investigator, The REVEAL Study</investigator_title>
  </responsible_party>
  <keyword>Mild Cognitive Impairment (MCI)</keyword>
  <keyword>Alzheimer's disease (AD)</keyword>
  <keyword>APOE</keyword>
  <keyword>genetics</keyword>
  <keyword>risk assessment</keyword>
  <keyword>education</keyword>
  <keyword>genetic counseling</keyword>
  <keyword>Mild Cognitive Impairment, So Stated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

